SLC transporters as therapeutic targets: emerging opportunities

被引:561
作者
Lin, Lawrence [1 ,2 ]
Yee, Sook Wah [1 ,2 ]
Kim, Richard B. [3 ]
Giacomini, Kathleen M. [1 ,2 ,4 ]
机构
[1] Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Sch Med, Dept Bioengn & Therapeut Sci, San Francisco, CA 94158 USA
[3] Univ Western Ontario, London Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, London, ON N6A 5A5, Canada
[4] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94158 USA
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
GENOME-WIDE ASSOCIATION; AMINO-ACID TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER-2; EXHIBITS ANTIDIABETIC EFFICACY; POSITRON-EMISSION-TOMOGRAPHY; GLUCOSE COTRANSPORTER SGLT1; DRUG-DRUG INTERACTIONS; CANCER-CELL-GROWTH; GLUTAMATE TRANSPORTER; BILE-ACID;
D O I
10.1038/nrd4626
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Solute carrier (SLC) transporters a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes have important roles in physiological processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.
引用
收藏
页码:543 / 560
页数:18
相关论文
共 214 条
  • [41] Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
    Forst, T.
    Guthrie, R.
    Goldenberg, R.
    Yee, J.
    Vijapurar, U.
    Meiningers, G.
    Stein, P.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (05) : 467 - 477
  • [42] The SLC3 and SLC7 families of amino acid transporters
    Fotiadis, Dimitrios
    Kanai, Yoshikatsu
    Palacin, Manuel
    [J]. MOLECULAR ASPECTS OF MEDICINE, 2013, 34 (2-3) : 139 - 158
  • [43] Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
    Franke, Andre
    McGovern, Dermot P. B.
    Barrett, Jeffrey C.
    Wang, Kai
    Radford-Smith, Graham L.
    Ahmad, Tariq
    Lees, Charlie W.
    Balschun, Tobias
    Lee, James
    Roberts, Rebecca
    Anderson, Carl A.
    Bis, Joshua C.
    Bumpstead, Suzanne
    Ellinghaus, David
    Festen, Eleonora M.
    Georges, Michel
    Green, Todd
    Haritunians, Talin
    Jostins, Luke
    Latiano, Anna
    Mathew, Christopher G.
    Montgomery, Grant W.
    Prescott, Natalie J.
    Raychaudhuri, Soumya
    Rotter, Jerome I.
    Schumm, Philip
    Sharma, Yashoda
    Simms, Lisa A.
    Taylor, Kent D.
    Whiteman, David
    Wijmenga, Cisca
    Baldassano, Robert N.
    Barclay, Murray
    Bayless, Theodore M.
    Brand, Stephan
    Buening, Carsten
    Cohen, Albert
    Colombel, Jean-Frederick
    Cottone, Mario
    Stronati, Laura
    Denson, Ted
    De Vos, Martine
    D'Inca, Renata
    Dubinsky, Marla
    Edwards, Cathryn
    Florin, Tim
    Franchimont, Denis
    Gearry, Richard
    Glas, Juergen
    Van Gossum, Andre
    [J]. NATURE GENETICS, 2010, 42 (12) : 1118 - +
  • [44] Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
    Fujimori, Yoshikazu
    Katsuno, Kenji
    Nakashima, Ikumi
    Ishikawa-Takemura, Yukiko
    Fujikura, Hideki
    Isaji, Masayuki
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (01) : 268 - 276
  • [45] Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
    Fujimori, Yoshikazu
    Katsuno, Kenji
    Ojima, Kazuma
    Nakashima, Ikumi
    Nakano, Shigeru
    Ishikawa-Takemura, Yukiko
    Kusama, Hiroshi
    Isaji, Masayuki
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 609 (1-3) : 148 - 154
  • [46] Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1
    Fumagalli, Elena
    Funicello, Marcella
    Rauen, Thomas
    Gobbi, Marco
    Mennini, Tiziana
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 578 (2-3) : 171 - 176
  • [47] Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
    Ganapathy, Vadivel
    Thangaraju, Muthusamy
    Prasad, Puttur D.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2009, 121 (01) : 29 - 40
  • [48] Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1
    Geier, Ethan G.
    Schlessinger, Avner
    Fan, Hao
    Gable, Jonathan E.
    Irwin, John J.
    Sali, Andrej
    Giacomini, Kathleen M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (14) : 5480 - 5485
  • [49] Genetics of Hyperuricemia and Gout: Implications for the Present and Future
    George, Ronald L.
    Keenan, Robert T.
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (02)
  • [50] Membrane transporters in drug development
    Giacomini, Kathleen M.
    Huang, Shiew-Mei
    Tweedie, Donald J.
    Benet, Leslie Z.
    Brouwer, Kim L. R.
    Chu, Xiaoyan
    Dahlin, Amber
    Evers, Raymond
    Fischer, Volker
    Hillgren, Kathleen M.
    Hoffmaster, Keith A.
    Ishikawa, Toshihisa
    Keppler, Dietrich
    Kim, Richard B.
    Lee, Caroline A.
    Niemi, Mikko
    Polli, Joseph W.
    Sugiyama, Yuicchi
    Swaan, Peter W.
    Ware, Joseph A.
    Wright, Stephen H.
    Yee, Sook Wah
    Zamek-Gliszczynski, Maciej J.
    Zhang, Lei
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) : 215 - 236